

Global EYLEA® (aflibercept) 8 mg real-world evidence

Real-world outcomes in previously treated patients with nAMD and DMO

Data from the IRIS Registry and Vestrum Health Retina database

nAMD

These data are from real patients. Individual results may vary.


Study design in patients with nAMD:

- From the IRIS Registry and Vestrum database, **58,638 and 23,338 patients**, respectively, received EYLEA 8 mg on the index date.* After applying the eligibility criteria, **38,535 patients from IRIS** and **12,847 patients from Vestrum** were included in the final cohorts.
- Treatment intervals** were assessed in eyes that were consistently treated with anti-VEGF therapy and received ≥ 1 post-initial dosing phase injection.
- The **last observed treatment intervals** with EYLEA 8 mg were assessed during the **baseline period and after the initial dosing phase**. Safety parameters were not assessed in this analysis.

Patient demographics for patients with nAMD


	IRIS Registry	Vestrum database
Patients in final cohort, N	38,535	12,847
Mean age, years	80.6	81.2
Female, %	60	63
Fellow eye treated on the index date, n	7,340	2,253

Previous treatment




Extended treatment intervals with EYLEA 8 mg

Change in treatment interval over time in eyes with a pre-switch interval of 4 to <6 weeks†




Mean (SD) change: **+22 (19) days**




Mean (SD) change: **+24 (20) days**

Change in treatment interval over time in eyes with a pre-switch interval of ≥ 6 to 8 weeks‡



Mean (SD) change: **+18 (23) days**



Mean (SD) change: **+19 (22) days**

EYLEA 8 mg provided extended treatment intervals regardless of prior treatment interval or prior treatment

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.

Data may not add up to 100% owing to rounding.

*The index date was the date of the first EYLEA 8 mg injection. †Among eyes that were consistently treated: ≥ 6 months of treatment prior to switch with an average pre-switch injection interval of 4 to <6 weeks and received ≥ 1 post-initial dosing phase EYLEA 8 mg injection. ‡Among eyes that were consistently treated: ≥ 6 months of treatment prior to switch with an average pre-switch injection interval of ≥ 6 to 8 weeks and received ≥ 1 post-initial dosing phase EYLEA 8 mg injection.

Abbreviations:

DMO, diabetic macular oedema; **nAMD**, neovascular age-related macular degeneration; **SD**, standard deviation; **VEGF**, vascular endothelial growth factor.

Reference:

Hung JH et al. Presented at the Annual Scientific Meeting of The Retina Society; Chicago, IL, USA, 10-13 September 2025.

May 2026 | PP-EYL_8mg-GB-1046

© Bayer plc. ® Registered trademark of BAYER AG, Germany.

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.

Either click [here](#) or scan the QR code for prescribing information and adverse event reporting information. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.




DMO

These data are from real patients. Individual results may vary.

Study design in patients with DMO:



- From the IRIS Registry and Vestrum database, **30,724 and 13,820 patients**, respectively, received EYLEA 8 mg on the index date.* After applying eligibility criteria, **13,820 patients from IRIS and 5,664 patients from Vestrum** were included in the final cohorts.
- Treatment intervals were assessed in eyes that were consistently treated with anti-VEGF therapy prior to switching to EYLEA 8 mg and received ≥ 1 post-initial dosing phase injection with EYLEA 8 mg.
- The last observed treatment intervals with EYLEA 8 mg were assessed during the **baseline period and after the initial dosing phase**. Safety parameters were not assessed in this analysis.

Patient demographics for patients with DMO		
	IRIS Registry	Vestrum database
Patients in final cohort, N	13,820	5,664
Mean age, years	66.1	65.9
Female, %	45	45
Fellow eye treated on the index date, n	4,802	1,658





Extended treatment intervals with EYLEA 8 mg

Change in treatment interval over time in eyes with a pre-switch interval of 4 to <6 weeks†



Change in treatment interval over time in eyes with a pre-switch interval of ≥ 6 to 8 weeks‡



EYLEA 8 mg provided extended treatment intervals regardless of prior treatment interval or prior treatment

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile. Data may not add up to 100% owing to rounding. *The index date was the date of the first EYLEA 8 mg injection. †Among eyes that were consistently treated: ≥ 6 months of treatment prior to switch with an average pre-switch injection interval of 4 to <6 weeks and received ≥ 1 post-initial dosing phase EYLEA 8 mg injection. ‡Among eyes that were consistently treated: ≥ 6 months of treatment prior to switch with an average pre-switch injection interval of ≥ 6 to 8 weeks and received ≥ 1 post-initial dosing phase EYLEA 8 mg injection.

Abbreviations:
DMO, diabetic macular oedema; SD, standard deviation; VEGF, vascular endothelial growth factor.
Reference:
Javaheri M et al. Presented at the Annual Scientific Meeting of The Retina Society 2025; Chicago, IL, USA, 10-13 September 2025.

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right. Either click [here](#) or scan the QR code for prescribing information and adverse event reporting information. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

